Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-05T05:11:42.615Z Has data issue: false hasContentIssue false

The Bitterest Pills: The Troubling Story of Antipsychotic Drugs By Joanna Moncrieff. Palgrave Macmillan. 2013. £19.99 (pb). 296 pp. ISBN: 9781137277435

Published online by Cambridge University Press:  02 January 2018

Duncan Double*
Affiliation:
Norfolk and Suffolk NHS Foundation Trust, Victoria House, 28 Alexandra Road, Lowestoft NR32 1PL, UK. Email: dbdouble@dbdouble.co.uk
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2014 

This is an important book. You might think I would say that as a member of the Critical Psychiatry Network, like the author, Joanna Moncrieff, senior clinical lecturer at University College London. However, I do think her critique has a sound academic grounding and engages with public concerns about antipsychotic medication.

The book describes the extent to which the prescription of antipsychotics is marketing-based rather than evidence-based. Chlorpromazine, of course, was the first drug seen as having a specific role in the treatment of mental illness. Moncrieff, instead, emphasises the non-specific nature of antipsychotic effects, which she frames by promoting a drug-centred rather than disease-centred model of their action. Nonetheless, she says that antipsychotics can ‘help individuals gain relief from intense and intrusive psychotic experiences or destructive emotional states’ (p. 18). By this she means more than their placebo effect and believes they can be of value as emotional suppressants. I would encourage you not to dismiss her approach as unbalanced. Despite what may seem like niggling overstatement at some points, she does present a genuine argument, with which I think it is important to engage.

She describes the wish-fulfilling nature of the dopamine theory of schizophrenia. She also makes a stronger case than even I was aware of for ventricular enlargement in schizophrenia being a drug-induced phenomenon. Historically, as she points out, there has been denial in psychiatry about traditional antipsychotics causing tardive dyskinesia and atypical antipsychotics producing the metabolic syndrome. Her summary critique of the early intervention approach also seems to me to be one of the best available.

I am sure this book will be too sceptical for most psychiatrists. It may seem to undermine psychiatry’s cultural system. Personally, I think psychiatry needs to face up to the truth about the psychopharmacological revolution, rather than continuing to rely on its aura of factuality. Even the past editor of this Journal Professor Peter Tyrer agrees Reference Tyrer1 we should call an end to the post-chlorpromazine era. I hope Jo’s book makes a significant contribution to this debate.

References

1 Tyrer, P. From the Editor’s desk. Br J Psychiatry 2012; 201: 168.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.